Published in J Infect Dis on August 15, 2008
Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev (2009) 3.61
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med (2009) 2.59
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
The human antibody response to dengue virus infection. Viruses (2011) 1.79
Immunological serotype interactions and their effect on the epidemiological pattern of dengue. Proc Biol Sci (2009) 1.75
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis (2009) 1.57
Cardiac function in Vietnamese patients with different dengue severity grades. Crit Care Med (2012) 1.56
Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol (2012) 1.36
Clinical and virological features of Dengue in Vietnamese infants. PLoS Negl Trop Dis (2010) 1.35
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol (2009) 1.27
Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol (2010) 1.20
Dengue viruses cluster antigenically but not as discrete serotypes. Science (2015) 1.12
Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis (2010) 1.04
First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog (2014) 1.02
Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci Rep (2011) 1.00
Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog (2014) 0.98
CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol (2014) 0.98
HLA class I and class II associations in dengue viral infections in a Sri Lankan population. PLoS One (2011) 0.96
Variation in vector competence for dengue viruses does not depend on mosquito midgut binding affinity. PLoS Negl Trop Dis (2011) 0.96
Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J Immunol (2012) 0.95
Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines (2013) 0.94
Serologic imprint of dengue virus in urban Haiti: characterization of humoral immunity to dengue in infants and young children. Am J Trop Med Hyg (2011) 0.94
A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection. Am J Pathol (2011) 0.91
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio (2015) 0.91
NK Cells during Dengue Disease and Their Recognition of Dengue Virus-Infected cells. Front Immunol (2014) 0.90
Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol (2013) 0.90
Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever. PLoS One (2012) 0.88
Evasion of the human innate immune system by dengue virus. Immunol Res (2012) 0.87
Dengue and soluble mediators of the innate immune system. Trop Med Health (2011) 0.87
The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal out-bred mice resulting in lethal multi-organ disease. PLoS One (2011) 0.86
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology (2011) 0.85
CD8+ T lymphocyte expansion, proliferation and activation in dengue fever. PLoS Negl Trop Dis (2015) 0.83
A birth cohort study of viral infections in Vietnamese infants and children: study design, methods and characteristics of the cohort. BMC Public Health (2013) 0.83
Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8(+) T cell response. Nat Immunol (2017) 0.80
Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol (2014) 0.78
Differential expression of Toll-like receptors in dendritic cells of patients with dengue during early and late acute phases of the disease. PLoS Negl Trop Dis (2013) 0.77
Lack of clinical manifestations in asymptomatic dengue infection is attributed to broad down-regulation and selective up-regulation of host defence response genes. PLoS One (2014) 0.77
Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies. BMC Res Notes (2012) 0.77
Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage. PLoS Negl Trop Dis (2016) 0.77
Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice. Med Microbiol Immunol (2014) 0.76
Immunosuppressive effects and mechanisms of leflunomide in dengue virus infection of human dendritic cells. J Clin Immunol (2011) 0.76
Placental Transfer of Dengue Virus (DENV)-Specific Antibodies and Kinetics of DENV Infection-Enhancing Activity in Brazilian Infants. J Infect Dis (2016) 0.76
Epidemiology of Dengue Among Children Aged < 18 Months-Puerto Rico, 1999-2011. Am J Trop Med Hyg (2015) 0.75
Pathogenesis of vascular leak in dengue virus infection. Immunology (2017) 0.75
Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient Mice. PLoS Negl Trop Dis (2016) 0.75
Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate. Plant Biotechnol J (2017) 0.75
Dengue Virus Induces NK Cell Activation through TRAIL Expression during Infection. Mediators Inflamm (2017) 0.75
Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. J Virol (2017) 0.75
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 11.44
Dengue: an update. Lancet Infect Dis (2002) 9.02
A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg (1988) 8.54
Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A (1994) 7.76
Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med (2003) 6.25
Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol (1984) 5.62
Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg (1989) 4.79
Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis (2002) 4.67
Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg (1988) 4.65
Risk factors in dengue shock syndrome. Am J Trop Med Hyg (1997) 3.83
Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis (1999) 2.96
Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis (2007) 2.89
A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996. Am J Trop Med Hyg (1999) 2.78
Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis (2005) 2.78
Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol (2002) 2.62
Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis (2004) 2.43
Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis (2002) 2.03
Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis (2006) 1.99
Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis (2007) 1.88
Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis (1999) 1.82
Dengue virus induces expression of CXC chemokine ligand 10/IFN-gamma-inducible protein 10, which competitively inhibits viral binding to cell surface heparan sulfate. J Immunol (2006) 1.38
Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology (2001) 1.33
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am J Trop Med Hyg (2001) 1.16
Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine (2007) 1.03
The global distribution and burden of dengue. Nature (2013) 27.92
Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med (2005) 15.53
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med (2006) 14.21
Typhoid fever. N Engl J Med (2002) 12.96
Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med (2004) 11.31
Dengue: a continuing global threat. Nat Rev Microbiol (2010) 9.96
Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med (2005) 6.47
Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. N Engl J Med (2002) 5.24
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Evolutionary history of Salmonella typhi. Science (2006) 5.00
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ (2008) 4.11
The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog (2008) 3.79
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
The WHO dengue classification and case definitions: time for a reassessment. Lancet (2006) 3.69
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol (2003) 3.67
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med (2016) 3.59
Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell (2013) 3.49
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Negl Trop Dis (2009) 3.30
Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis (2010) 3.21
Streptococcus suis meningitis in adults in Vietnam. Clin Infect Dis (2008) 3.18
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis (2012) 3.06
Evaluation of diagnostic tests: dengue. Nat Rev Microbiol (2010) 2.91
Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis (2009) 2.89
Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis (2007) 2.89
Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial. Crit Care Med (2013) 2.88
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother (2007) 2.73
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis (2011) 2.70
Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness Environ Med (2012) 2.70
Into the eye of the cytokine storm. Microbiol Mol Biol Rev (2012) 2.58
Transparent development of the WHO rapid advice guidelines. PLoS Med (2007) 2.57
Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. Lancet Infect Dis (2011) 2.54
An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.47
Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med (2009) 2.47
Progress towards a dengue vaccine. Lancet Infect Dis (2009) 2.45
The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis (2005) 2.38
Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis (2010) 2.33
Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis (2005) 2.29
Policy: An intergovernmental panel on antimicrobial resistance. Nature (2014) 2.22
Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg (2011) 2.17
Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia. PLoS Negl Trop Dis (2010) 2.17
High-throughput genotyping of Salmonella enterica serovar Typhi allowing geographical assignment of haplotypes and pathotypes within an urban District of Jakarta, Indonesia. J Clin Microbiol (2008) 2.14
Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis (2009) 2.13
Liver involvement associated with dengue infection in adults in Vietnam. Am J Trop Med Hyg (2010) 2.10
Clinical characteristics of Dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. Clin Infect Dis (2013) 2.08
Population-level antibody estimates to novel influenza A/H7N9. J Infect Dis (2013) 2.03
Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect Dis (2011) 2.03
Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother (2006) 2.01
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00
Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet (2011) 2.00
Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness. PLoS Negl Trop Dis (2008) 1.99
Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses. BMC Infect Dis (2010) 1.97
Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS One (2010) 1.96
Unidentified acids of strong prognostic significance in severe malaria. Crit Care Med (2004) 1.95
Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: diagnostic value and relationship to disease severity and outcome. J Immunol (2006) 1.92
Avian influenza A (H5N1). J Clin Virol (2005) 1.90